Real-world data firm Litmus Health published its first census of wearable devices for clinical research.
Respiratory care specialist Vapotherm raised $56 million in an IPO on the New York Stock Exchange under the symbol VAPO.
The FDA granted a de novo clearance to Atlantic Therapeutics’ electrical muscle stimulator for women, for treating stress urinary incontinence.
Livongo and the University of California, San Francisco, launched a randomized, controlled trial that will recruit 300 adults with Type 2 diabetes.
Days after poaching a health system executive to pull together its disparate healthcare ventures, Google moved to reabsorb DeepMind’s health business.
Cardiva Medical’s resorbable vascular closure reduced bed rest and opioid use following ablation procedures in a clinical study.
Nyxoah has raised another €15 million (about $17 million) in financing to help commercialize its nerve stimulation treatment for sleep apnea.
Eko's AI could allow a broader number of physicians to digitally screen patients for heart murmurs without needing a trained cardiologist.
Medtronic’s final, five-year study data showed the durability of its drug-coated angioplasty balloon in peripheral artery disease.
Fierce 15 winner MaxQ AI received an FDA clearance for its artificial intelligence software that rapidly detects brain bleeds in CT scans.
